Perplexed by PPI s Should I be Worried? James R Gray Gastroenterology Vancouver
|
|
- Nicholas Cook
- 6 years ago
- Views:
Transcription
1 Perplexed by PPI s Should I be Worried? James R Gray Gastroenterology Vancouver
2 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic, or mechanical, including photocopying, recording, or information storage and retrieval systems without prior written permission of Sea Courses Inc. except where permitted by law. Sea Courses is not responsible for any speaker or participant s statements, materials, acts or omissions.
3 Anti-Secretory Drug Consumption Am J Gastro 2016
4 Overuse of Antisecretory Therapy in the Ambulatory Care Setting Am J Managed Care 2010; 16: e228
5 The Concerns Fractures Drug-drug interactions Infections Clostridium difficile infections Enteric infections Pneumonia Micronutrient Malabsorption Vitamin B12 deficiency Hypomagnesemia Gastric mucosal changes Neoplasia Microscopic colitis Spontaneous bacterial peritonitis in cirrhotics Interstitial nephritis Dementia Death Acid rebound
6 PPIs and Adverse Events with Proven and Unproven Causality Nat Rev Gastro Hep doi /nrgastro
7 The Issue Balancing Potential Harms and Documented Benefits
8 PPI s and Fractures Data from retrospective observational studies Reported risks are low Mechanism for an association not clear
9 Association between continuous exposure to proton pump inhibitors and osteoporosis-related fractures Targownik CMAJ 2008;179:
10 PPI s and Bone Health Women s Health Initiative (n= 1,005,126 person year F/U) PPI Non-User 1 PPI User < 1 year 1.27 ( ) PPI User 1-3 years 1.19 ( ) PPI User > 3 years 1.30 ( ) Fracture Risk (Hip, spine, forearm) H2RA Non-User 1 H2RA User < 1 year 1.09 ( ) H2RA User 1-3 years 1.08 ( ) H2Ra User > 3 years 1.06 ( ) Gray. Arch Int Med 2010; 170: 765
11 Lack of Duration Effect of PPI Exposure and Hip Fracture Am J Gastro 2011; 106: 1209
12 PPIs and Hip Fracture NNH = 2,672 Am J Gastro 2011; 106: 1209
13 PPI s and Bone Health Theoretical Explanations Calcium malabsorption? Impaired bone metabolism? Hyperparathyroidism Reduced plasma homocysteine secondary to malabsorption of folate, B12 and riboflavin by acid suppression? (Proton pump inhibition of osteoclast activity)
14 Dietary Calcium Gastric Acid Release Ionized Calcium Low serum Calcium Calcium absorption Parathyroid activation PTH release Osteoclastic activity Bone mass, fracture risk
15 Inhibiting Gastric Acid for 5 days does not Affect Calcium Absorption J Bone and Min Res 2010; 25: 2205
16 30 days of Omeprazole does not affect calcium absorption J Bone and Min Res 2010; 25: 2786
17 Lack of Effect of PPI s on Bone Mineral Density over 10 Years Follow-up Hip Femur Lumbar Spine Continuous PPI use 0.9% ( %) -0.5% ( %) -0.7% ( %) PPI use > 50 years old 0.1% ( %) -0.9% ( %) -0.5% ( %) Current PPI use -0.5% ( %) -0.6% ( %) -0.1% ( %) Targownik. Am J Gastro 2012; 107: 1361
18 Arch Int Med 2010; 170: 763
19 PPI s and Fractures Conclusion Number Needed to Harm (NNH) 234 post menopausal diabetic women 1000 s young women or men Pharmacotherapy 2008; 28: 951 J Clin Endo Metab 2006; 91: 3404
20 PPIs and Clopidogrel Is There GI Benefit or Cardiovascular Harm?
21 Clopidogrel Proton Pump Inhibitor CYP-4502C19 Active metabolite Inactive Metabolite
22 PPI s and Clopidogrel Initial concerns from in vitro studies of platelet reacitivity leading to FDA warning Best quality clinical studies fail to show adverse CV outcomes PPI co-therapy reduces UGI complications
23 PPI s and Platelet Function No clear or consistent interaction in platelet function studies Kwok. Drug Safety 2012; 35: 127 Gastro 2011; 140: 791
24 Benefit of Omeprazole with Clopidogrel and ASA in Coronary Artery Disease (COGENT study) Probability of Remaining Free of a Primary GI Event NEJM 2010; 363: 1909
25 No Difference in Serious CVD Outcome With or Without PPI Ray. Ann Int Med 2010; 152: 337
26 Mortality Rates from UGI Bleed or Perforation Over Time Date of Publication All Cases Mortality (%) Cases Using NSAIDs (%) Before ( ) 14.7 ( ) ( ) 20.9 ( ) BMC Gastro 2009; 9:41
27 NSAID Ulcer Complications: Risk Factors Prior complicated ulcer 13.5 Multiple NSAIDs (aspirin) 9 High dose Anticoagulant Prior uncomplicated ulcer Age> H. pylori 3.5 Steroids Odds ratio Gabriel SEl. Ann Intern Med 1991;115(10):787-96; Garcia Rodriguez LA. Lancet 1994;343:769; Silverstein FEl. Ann Intern Med 1995;123(4):241-9; Huang JQl. Lancet 2002;359:14
28 Clopidogrel vs Placebo + ASA in Acute Coronary Syndrome (n=12,562) CURE Trial. NEJM 2001; 345: 494
29 Reduced Adverse GI Events with Clopidogrel and ASA by PPI Drug Safety 2011; 34: 47
30 Outcomes with Clopidogrel Alone or with PPI Open Heart 2015; 2: e000248
31 Outcomes with Clopidogrel alone or with PPI Open Heart 2015; 2: e000248
32 Reduced Risk of GI Bleeding by Taking PPIs and NSAIDs in Post-MI Patients BMJ 2015; 351: h5096
33
34 J Am Coll Card 2008; 52: 1502
35 Drugs don t work in patients who don t take them. C Everett Koop US Surgeon General
36 PPIs and Infections Gastrointestinal infections C difficle Community or travellers enteritis Respiratory infections Community acquired Hospital acquired
37 Shift of Gut Microbiome Towards Oral Microbiome in PPI Users Gut 2016; 65: 740
38 Acid Suppression and Enteric Infections H2RA PPI Am J Gastro 2007; 102: 2047
39 Risk of C difficile Infection with PPI Use NNH = 67 Am J Gastro 2012; 107: 1011
40 PPI s and C difficile Estimates of Risk Population NNT for harm Unselected hospital admissions without PPI 67 (48-110) PPI users admitted to hospital 22 (9-670) Hospital admissions with antibiotics 28 (21-42) Hospital admissions without antibiotics 202 ( ) Community patients 899 ( ) Kwok. Am J Gastro 2012; 107: 1011
41 Microscopic Colitis Chronic watery diarrhea > 60 years old Females > males Represents etiology in 7.5% with chronic diarrhea Two subtypes Lymphocytic Collagenous Cause unknown but several drug associations
42 Risk of Microscopic Colitis and Drugs APT 2016; 43: 1004
43 PPI s and Community Acquired Pneumonia (n= 364, 683) Adjusted Relative Risk Current PPI use 1.89 ( ) Current H2RA use 1.63 ( ) Low dose PPI 1.23 ( ) Standard dose PPI 1.94 ( ) High dose PPI 2.28 ( ) Laheij. JAMA 2004; 292: 1955
44 PPI s and Hospital-Acquired Pneumonia (n=63,878 admissions) Adjusted Relative Risk Hospital-acquired pneumonia 1.3 ( ) Aspiration pneumonia 1.4 ( ) Non-aspiration pneumonia 1.2 ( ) PPI use 1.3 ( ) H2RA use 1.2 ( ) Herzig. JAMA 2009; 301: 2120
45 Duration of Acid suppression and Risk of Pneumonia Nat Rev Gastro Hep 2012; 9: 132
46 Comorbidities of Patients Receiving PPIs and Risk of Developing Pneumonia Nat Rev Gastro Hep 2012; 9: 132
47 Lack of Association Between PPI Use and Community Acquired Pneumonia Gut 2014; 63: 552
48 PPIs and Absorption B12 Iron Magnesium
49 PPI s and B12 No association with long-term PPI use and B12 status Den Elzen. APT 2008; 27: 491 Valuck. J Clin Epidem 2004; 57: 422 B12 deficiency more likely after more than 2 years of PPI Lam. JAMA 2013; 310: 2435
50 PPI s and Iron Absorption No evidence for iron deficiency with PPI use Stewart. APT 1998; 12: 83
51 PPI s and Hypomagnesemia 36 cases since first reported 2006 PPI use 2 weeks to 13 years (mean 5.5 yrs) Class effect - all PPI s Beware with loop diuretics Fast recovery after discontinuation but recurrence with re-challenge Mechanism not clear, not urine excretion Hess. APT 2012; 36: 405 Mackay. QJMed 2010; 103: 387
52 Low Prevalence of Hypomagnesemia in Long-term Users of PPIs Clin Gastro Hep 2016; 14: 317
53 PPI s and Acute Interstitial Nephritis 64 cases (60% female, mean age 78) PPI use mean of 13 weeks Average recovery 35.5 weeks, 3 required dialysis Initial symptoms: nausea, vomiting, fever Sierra. APT 2007; 26: 545 Geevasinga. Clin Gastro Hep 2006; 4: 597
54 Concomitant Meds in PPI Users With Interstitial Nephritis N=60 N=60 N=34 APT 2007; 26: 545
55 Chronic Kidney Disease and PPI Use JAMA Int Med 2016; 176: 238
56 Association of PPI and Dementia JAMA Neurol Feb 15, 2016
57 Am J Gastro 2017; 112: 1084
58 Cumulative Incidence of Ischemic Stroke Over 120 Days Am J Gastro 2017; 112: 1084
59 Duration of PPI Exposure and Risk of Death N=166,098 BMJ Open July 3, 2017
60 The Challenge of Observational Studies Comorbidities in Patients on PPIs Nature Reviews Gastro Hep 2012; 9: 132
61 PPI s and Cancer Risk Colorectal cancer No increased risk PPI Use Never or rare 1.0 Adjusted Odds Ratio Recent 1.14 ( ) Former 1.11 ( ) Robertson. Gastro 2007; 133: 755 van Soest. Am J Gastro 2008; 103: 966 Yang. Gastro 2007; 133: 748
62 PPI s and Cancer Risk Gastric cancer No increased risk (accounting for reverse causation with a one year lag time) Medication exposure Risk of gastric cancer PPI use 1.2 ( ) H2RA use 1.2 ( ) Poulsen. Br J Cancer 2009; 100: 1503
63 Reported Associations with PPI Use and Adverse Events Adverse Event Hazard Ratio 95% CI Hip fracture with PPI use > 1 year Hip fracture with long-term PPI use Community acquired pneumonia Clostridium difficile infection Acute interstitial nephritis Acute kidney injury Hypomagnesaemia Myocardial infarction Dementia Nat Rev Gastro Hep. March 16, 2016
64 Acid Rebound Gastro 2009; 137: 20
65 Acid-Related Symptoms After Withdrawal of PPI in Healthy Volunteers Gastro 2009; 137: 80
66 Summary PPIs effective for erosive and non-erosive UGI disorders Generally well tolerated but potential side effects to be considered Concerns for alleged risks poorly supported but include fractures, Clopidogrel interaction, pneumonia and malabsorption Strongest risk associations are with enteric infections and interstitial nephritis
67 References Adverse effects associated with PPIs. JAMA Int Med 2016; 176: 172 Safety of Long-term PPI therapy. Best Pract Res Clin Gastro 2013; 27: 443 Side effects and Complications of PPI Use: Dissecting the Evidence. Clin Gastro Hep 2013; 11: 458 Prescribing PPIs. Is it time to pause and rethink? Drugs 2012; 72: 437 A Benefit-risk Assessment of PPIs in the Elderly. Drugs Aging 2014; 31: 263 PPIs and MI. Gastroenterol 2015; 149: 830
Practical Guide to Safety of PPIs What to Tell Your Patient. Proton Pump Inhibitors
Practical Guide to Safety of PPIs What to Tell Your Patient Joel E Richter, MD, FACP, MACG Professor and Director Division of Digestive Diseases and Nutrition Joy Culverhouse Center for Esophageal Diseases
More informationAppropriate Use of Proton Pump Inhibitors (PPIs) Anderson Mabour, Pharm.D., BCPS Clinical Pharmacy Specialist
Appropriate Use of Proton Pump Inhibitors (PPIs) Anderson Mabour, Pharm.D., BCPS Clinical Pharmacy Specialist Disclosures I have no actual or potential conflicts of interest to report in relation to this
More informationPPIs: Good or Bad? 1. Basics of PPIs. Gastric Acid Basics. Outline. Gastric Acid Basics. Proton Pump Inhibitors (PPI)
Outline Quick basics on Proton Pump Inhibitors (PPIs) PPIs: Good or Bad? What are potential risks of PPI therapy? How to approach your patients American Gastroenterology Association (AGA) recommendations
More informationLONG -TERM USE OF PPIS: INDICATIONS, BENEFITS AND HARMS. Jihane Naous, M.D.
LONG -TERM USE OF PPIS: INDICATIONS, BENEFITS AND HARMS Jihane Naous, M.D. Objectives Identify the conditions supported by AGA/ACG guidelines necessitating long-term use of daily PPIs, Recognize which
More informationSafety Of. long-term PPI. Layli Eslami, MD Tehran, 1393
Safety Of long-term PPI Layli Eslami, MD Tehran, 1393 n The introduction of PPIs in the late 1980s optimized the medical treatment of acidrelated disorders n In some cases such as GERD patients given the
More informationRisk of GI Bleeding and Use of PPIs
Risk of GI Bleeding and Use of PPIs ESC 211 August 28, 211 Marc S. Sabatine, MD, MPH Chairman, TIMI Study Group Associate Physician, Cardiovascular Division, BWH Associate Professor of Medicine, Harvard
More informationCYP2C19-Proton Pump Inhibitors
CYP2C19-Proton Pump Inhibitors Cameron Thomas, Pharm.D. PGY2 Clinical Pharmacogenetics Resident St. Jude Children s Research Hospital February 1, 2018 Objectives: CYP2C19-PPI Implementation Review the
More informationHits and Myths of Diverticulosis. JR Gray Gastoenterology UBC
Hits and Myths of Diverticulosis JR Gray Gastoenterology UBC Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form
More informationA C A D E M I C D E TA I L I N G C H O O S I N G W I S E LY C O N F E R E N C E O C T 2 1, PA M M C L E A N - V E Y S E Y B S C P H A R M D R
PPI DEPRESCRIBING Canadian Deprescribing Network (CaDeN) goals are to: Reduce harm by raising awareness and cutting risky prescriptions for seniors by 50% by 2020. Promote health by ensuring access to
More informationProton Pump Inhibitors increase Cardiovascular risk in patient taking Clopidogrel
Proton Pump Inhibitors increase Cardiovascular risk in patient taking Clopidogrel Dr.A.K.M. Aminul Hoque Assoc. Prof. of Medicine. Dhaka Medical College. Clopidogrel Metabolism Clopidogrel is an inactive
More informationProton Pump Inhibitors:
Proton Pump Inhibitors: How bad could they be? Andrea Flanagan, Pharm.D. Iowa City VA Medical Center PGY-1 Pharmacy Resident Objectives for Pharmacists At the end of this presentation PHARMACISTS should
More informationAcid Control and Healing of EE are Related. Disclosures. Perspectives on the Risk-Benefit Ratio of PPI Therapy. Risk-Benefit Ratio of PPIs
Perspectives on the Risk-Benefit Ratio of PPI Therapy David C. Metz. MD Professor of Medicine Division of Gastroenterology University of Pennsylvania School of Medicine Disclosures Grant/Research Support
More informationAm J Gastroenterol 2010;105:
ACCF/ACG/AHA 2010 Expert Consensus Document Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document
More informationHoward K. Gogel, MD Southwest Gastroenterology Associates November 2017
Howard K. Gogel, MD Southwest Gastroenterology Associates November 2017 PPI indications and Overuse of PPIs Association vs causation (relative risk, odds ratios) Problems: Hypergastrinemia: ECL hyperplasia,
More informationBleeding Prevention in an Era of Expanding Combination Antithrombotic Therapies
Bleeding Prevention in an Era of Expanding Combination Antithrombotic Therapies Muthiah Vaduganathan, MD MPH Cardiovascular Medicine Brigham and Women s Hospital December 8 th, 2017 Disclosures None Key
More informationSESSION 3 11 AM 12:30 PM
SESSION 3 11 AM 12:30 PM for the Primary Prevention of Cardiovascular Disease: A Personalized Approach SPEAKER Samia Mora MD, MHS Presenter Disclosure Information The following relationships exist related
More informationRisky Business: Kicking the PPI Habit
Conflict of Interest Risky Business: Kicking the PPI Habit I have no actual or potential conflict of interest to disclose. Jason Morell, PharmD, BCPS Pharmacist Rush University Medical Center Objectives
More information2018 CONSENSUS UPDATES + RISKS/BENEFITS OF PPI USE
2018 CONSENSUS UPDATES + RISKS/BENEFITS OF PPI USE IN INFANT GERD SWEDISH MEDICAL CENTER JONAH ESSERS, MD, MPH OBJECTIVES Highlight the 2018 updates to infant GERD recommendations Provide an update on
More informationVimovo (delayed-release enteric-coated naproxen with esomeprazole)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.17.01 Subject: Vimovo Page: 1 of 5 Last Review Date: September 18, 2015 Vimovo Description Vimovo (delayed-release
More informationOral proton pump inhibitors (PPIs)
Treatment Guideline Oral proton pump inhibitors (PPIs) Introduction The high efficacy and low toxicity of proton pump inhibitors (PPIs) has contributed to their frequent prescription worldwide, often without
More informationMY PATIENT HAS READ THAT HIS PPI S MAY BE TROUBLE. NOW WHAT?
MY PATIENT HAS READ THAT HIS PPI S MAY BE TROUBLE. NOW WHAT? Clarence Wong MD FRCPC Associate Professor FACULTY/PRESENTER DISCLOSURE Faculty: Clarence Wong Relationships with commercial interests: Grants/Research
More informationSESSION 5 2:20 3:35 PM
SESSION 5 2:20 3:35 PM for the Primary Prevention of Cardiovascular Disease: A Personalized Approach SPEAKER Samia Mora MD, MHS Presenter Disclosure Information The following relationships exist related
More informationTHE EFFECTS OF LONG- TERM PROTON PUMP INHIBITORS USE AND MISUSE
THE EFFECTS OF LONG- TERM PROTON PUMP INHIBITORS USE AND MISUSE CONTENTS Overview Indications Over-prescribed in inappropriate conditions Side effects of long-term PPI use Conclusion OVERVIEW INDICATIONS
More informationClopidogrel Use in ACS and PCI: Clinical Trial Update
Clopidogrel Use in ACS and PCI: Clinical Trial Update Matthew J. Price MD Director, Cardiac Catheterization Laboratory, Scripps Clinic, La Jolla, CA Assistant Professor, Scripps Translational Science Institute
More informationSurveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management
Surveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management Jeffrey S Berger, MD, MS Assistant Professor of Medicine and Surgery Director of Cardiovascular Thrombosis Disclosures
More informationProton Pump Inhibitor De-prescribing Guidance
Amendment History Proton Pump Inhibitor De-prescribing Guidance VERSION DATE AMENDMENT HISTORY 1.0 2013 Previous version 2.0 September 2015 Comments Amendment to Flow chart and addition of Rationale page
More informationFARMACI E ALTE VIE DIGESTIVE NELL ANZIANO: UTILITÀ E LIMITI
FARMACI E ALTE VIE DIGESTIVE NELL ANZIANO: UTILITÀ E LIMITI Edoardo V. Savarino, MD, PhD Professor of Gastroenterology Department of Surgery, Oncology and Gastroenterology University of Padua Italy COMMON
More informationManagement of Dyspepsia
MPharm Programme Management of Dyspepsia Slide 1 of 28 Learning Objectives Understand the principles and wider implications underpinning evidence based therapeutics in the key clinical specialities Objectively
More informationComplications of Proton Pump Inhibitor Therapy. Gastroenterology 2017; 153:35-48 발표자 ; F1 김선화
Complications of Proton Pump Inhibitor Therapy Gastroenterology 2017; 153:35-48 발표자 ; F1 김선화 Background Proton pump inhibitors (PPIs) are among the most commonly prescribed medicines for gastroesophageal
More informationRefractory GERD. Kenneth R. DeVault, MD, FACG President American College of Gastroenterology Chair Department of Medicine Mayo Clinic Florida
Refractory GERD Kenneth R. DeVault, MD, FACG President American College of Gastroenterology Chair Department of Medicine Mayo Clinic Florida Objectives Define the terminology associated with refractory
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationBleeds in Cardiovascular Disease
Preventing Gastrointestinal Bleeds in Cardiovascular Disease Patients t on Aspirin i Joel C. Marrs, Pharm.D., BCPS Clinical Assistant Professor OSU/OHSU College of Pharmacy Pharmacy Practice IX (PHAR 766)
More informationEU RISK MANAGEMENT PLAN (EU RMP)
EU RISK MANAGEMENT PLAN (EU RMP) Active substance(s) (INN or common name): Esomeprazole Pharmaco-therapeutic group (ATC Code): A02B C05 Name of Marketing Authorisation Holder or Applicant: Strength and
More informationAN ARGUMENT FOR SURGERY FOR GASTRINOMA. Lauren Wilson R1 General Surgery
AN ARGUMENT FOR SURGERY FOR GASTRINOMA Lauren Wilson R1 General Surgery WHAT IS A GASTRINOMA? Gastrin secreting cells derived from multipotential stem cells of endodermal origin or enteroendocrine cells
More information11/19/2012. Comparison between PPIs G CELL. Risk ratio (95% CI) Patient subgroup. gastrin. S-form of omeprazole. Acid sensitive. coated.
REGULATION OF GASTRIC ACID SECRETION Comparison between PPIs Omeprazole Lansoprazole Rabeprazole Pantoprazole Esomeprazole gastrin G CELL + Acid sensitive Yes T1/2 30-60 minutes Main elimination Enteric
More informationMANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) Routine endoscopic investigation of patients of any age, presenting with dyspepsia
More informationTreating Hypertension in Individuals with Diabetes
Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any
More informationStressed Out: Evaluating the Need for Stress Ulcer Prophylaxis in the ICU
Stressed Out: Evaluating the Need for Stress Ulcer Prophylaxis in the ICU Josh Arnold, PharmD PGY1 Pharmacy Resident Pharmacy Grand Rounds November 8, 2016 2016 MFMER slide-1 Objectives Identify the significance
More informationDisclosures. Proton Pump Inhibitors Deprescribing? Deprescribing PPI Objectives. Deprescribing. Proton Pump Inhibitors (PPI) 5/28/2018.
Proton Pump Inhibitors Deprescribing? None Disclosures Chad Burski, MD Assistant Professor of Medicine UAB Gastroenterology Deprescribing PPI Objectives AR Why? Who? How? The mechanism of action of Proton
More information9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?
Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial
More informationNSAIDs: Side Effects and Guidelines
NSAIDs: Side Effects and James J Hale FY1 Department of Anaesthetics Introduction The non-steroidal anti-inflammatory drugs (NSAIDs) are a diverse group of drugs that have analgesic, antipyretic and anti-inflammatory
More informationProton Pump Inhibitors- Questions & Controversies. Farah Kablaoui, PharmD, BCPS, BCCCP
Proton Pump Inhibitors- Questions & Controversies Farah Kablaoui, PharmD, BCPS, BCCCP Disclosure Information Proton Pump Inhibitors: Questions & Controversies Farah Kablaoui I have no financial relationship
More information'Fake News' in GI: Getting to the Truth about Gluten, PEG 3350 and PPIs. Carlo Di Lorenzo, M.D
'Fake News' in GI: Getting to the Truth about Gluten, PEG 3350 and PPIs Carlo Di Lorenzo, M.D Twitter: @carlodilorenzo1 Disclosure I have the following financial relationships with the manufacturer(s)
More informationCytochrome P450 interactions
Cytochrome P450 interactions Learning objectives After completing this activity, pharmacists should be able to: Explain the mechanism of action of clopidogrel-ppi interaction Assess the risks and benefits
More informationPolicy Evaluation: Proton Pump Inhibitors (PPIs)
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More information4/26/2016. Practical Pharm Tips. Jonathan R White, PharmD, BCPS, BCACP
Practical Pharm Tips Jonathan R White, PharmD, BCPS, BCACP A day in the life of an adult in 2016 1 What to do when clinical trials hit! (the popular media) 2 Patient Case 1 In a clinical trial Jardiance
More informationEosinophilic Esophagitis. Another Reason Not to Swallow
Eosinophilic Esophagitis Another Reason Not to Swallow Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or
More informationPROTON PUMP INHIBITOR AND CLOPIDOGREL INTERACTION: Am J Gastroenterol Jan;105(1): Epub 2009 Nov 10.
PROTON PUMP INHIBITOR AND CLOPIDOGREL INTERACTION: FACT OR FICTION? 本檔僅供內部教學使用檔案內所使用之照片之版權仍屬於原期刊公開使用時, 須獲得原期刊之同意授權 Am J Gastroenterol. 2010 Jan;105(1):34-41. Epub 2009 Nov 10. Introduction Current consensus
More informationThe presence and development of gastric ulcers. Evaluation of Stress Ulcer Prophylaxis in a Family Medicine Residency Inpatient Service
Evaluation of Stress Ulcer Prophylaxis in a Family Medicine Residency Inpatient Service Heather A. Kehr, PharmD, BCPS, Carrie L. Griffiths, PharmD, R. Wesley Haynes, PharmD, Sonia Everhart, PharmD, BCPS,
More informationSimon Everett. Consultant Gastroenterologist, SJUH, Leeds. if this is what greets you in the morning, you probably need to go see a doctor
Simon Everett Consultant Gastroenterologist, SJUH, Leeds if this is what greets you in the morning, you probably need to go see a doctor Presentation Audit data and mortality NICE guidance Risk assessment
More informationFamily Medicine Clinical Pharmacy Forum Vol. 3, Issue 1 (January/February 2007)
1 Family Medicine Clinical Pharmacy Forum Vol. 3, Issue 1 (January/February 2007) Family Medicine Clinical Pharmacy Forum is a brief bi-monthly publication from the Family Medicine clinical pharmacists
More informationHot off the press. What s new and potentially relevant. Petr Polasek MD FRCPC FACC
Hot off the press What s new and potentially relevant Petr Polasek MD FRCPC FACC Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted
More informationInvestor Conference Call
Investor Conference Call Data from the Phase III COMPASS trial, A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery
More informationSurgery for Complications of Peptic Ulcer Disease (Definitive Treatment)
Surgery for Complications of Peptic Ulcer Disease (Definitive Treatment) Amid Keshavarzi, MD UCHSC Grand Round 3/20/2006 Department of Surgery Introduction Epidemiology Pathophysiology Clinical manifestation
More informationGuidelines for the Management of Dyspepsia and GORD. Gastroenterology/ Acute Adult Governance. Drugs and Therapeutics Committee
Guidelines for the Management of Dyspepsia and GORD Document type: Version: 3.0 Author (name): Author (designation): Validated by Prescribing Dr. G. Lipscomb Date validated October 2015 Ratified by: Date
More informationNSAIDs Change Package 2017/2018
NSAIDs Change Package 2017/2018 Aim: To Reduce harm to patients from Non-Steroidal Anti-inflammatory Drugs (NSAIDs) in primary care Background A key aim of the Safety in Practice programme is to reduce
More informationAntiplatelets in cardiac patients with suspected GI bleeding
Antiplatelets in cardiac patients with suspected GI bleeding Acute GI bleeding is a common major medical emergency. In the 2007 UK-wide audit, overall mortality of patients admitted with acute GI bleeding
More informationHow Long Patietns Will Be on Dual Antiplatelet Therapy?
How Long Patietns Will Be on Dual Antiplatelet Therapy? Ron Waksman,, MD, FACC Professor of Medicine (Cardiology) Georgetown University Associate Director, Division of Cardiology, Washington Hospital Center
More informationFREQUENTLY ASKED QUESTIONS
FREQUENTLY ASKED QUESTIONS Frequently Asked Questions: Table of Contents What clinical clues help distinguish between nociceptive and neuropathic pain? Can I combine treatments? Why should the treatment
More informationRABEPRAZOL 10mg and 20mg Gastro-resistant Tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER RABEPRAZOL 10mg and 20mg Gastro-resistant Tablets RABEPRAZOLE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet
More informationS. Sandberg-Lewis, ND, DHANP
Functional Gastroenterology Webinar One 6-28-13 S. Sandberg-Lewis, ND, DHANP Proton pump inhibitors- Effects on: secretion gastric mucosa food allergy bile reflux Barrett metaplasia and dysplasia esophageal
More informationNutritional Considerations with Obesity and Bariatric Surgery. Presented by Dr. Ron Grabowski
Nutritional Considerations with Obesity and Bariatric Surgery Presented by Dr. Ron Grabowski January 25, 2010 Nutritional Considerations with Obesity and Bariatric Surgery Presented by Dr. Ron Grabowski
More informationGlucose Control: Does it lower CV risk?
Glucose Control: Does it lower CV risk? Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic,
More informationProton pump inhibitors: balancing the benefits and risks of long-term use
Proton pump inhibitors: balancing the benefits and risks of long-term use Chenlu (Maria) Tian, MD Assistant Professor Digestive and Liver Disease University of Texas Southwestern Medical Center This is
More informationHelicobacter pylori. Objectives. Upper Gastrointestinal Bleeding Peptic Ulcer Disease
Upper Gastrointestinal Bleeding Peptic Ulcer Disease Pharmacotherapy Issues in Acute Management and Secondary Prevention Peter J. Zed, B.Sc., B.Sc.(Pharm), Pharm.D. Pharmacotherapeutic Specialist - Emergency
More informationEvolution and Medicine. Dr. Peter J. Lin Director Primary Care Initiatives Canadian Heart Research Centre
Evolution and Medicine Dr. Peter J. Lin Director Primary Care Initiatives Canadian Heart Research Centre Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced,
More informationCARDIOVASCULAR RISK and NSAIDs
CARDIOVASCULAR RISK and NSAIDs Dr. Syed Ghulam Mogni Mowla Assistant Professor of Medicine Shaheed Suhrawardy Medical College, Dhaka INTRODUCTION NSAIDs are most commonly prescribed drugs Recent evidence
More informationOVERALL SUMMARY OF THE SCIENTIFIC EVALUATION OF LOSEC AND ASSOCIATED NAMES (SEE ANNEX I)
ANNEX II SCIENTIFIC CONCLUSIONS AND GROUNDS FOR AMENDMENT OF THE SUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET PRESENTED BY THE EMEA 21 SCIENTIFIC CONCLUSIONS OVERALL SUMMARY OF THE
More informationDisclosure. Overview. Objectives. Five Noteworthy Outpatient Publications. Factors Affecting Antibiotic Prescribing 7/24/2013
47 th Annual Meeting August 2-4, 2013 Orlando, FL Five Noteworthy Outpatient Publications R. Vandervoort, Pharm.D. Disclosure I do not have a vested interest in or affiliation with any corporate organization
More informationIroko Pharmaceuticals Announces Acceptance for Filing of ZORVOLEX snda for the Treatment of Osteoarthritis Pain in Adults
Iroko Pharmaceuticals Announces Acceptance for Filing of ZORVOLEX snda for the Treatment of Osteoarthritis Pain in Adults First Lower Dose NSAID Using SoluMatrix Fine Particle Technology to be Reviewed
More informationMedication Guide. Omeprazole and Sodium Bicarbonate Capsules (oh mep ra zole and soe dee um bye kar bo nate)
Medication Guide Omeprazole and Sodium Bicarbonate Capsules (oh mep ra zole and soe dee um bye kar bo nate) Read this Medication Guide before you start taking omeprazole and sodium bicarbonate capsules
More informationProton Pump Inhibitors Drug Class Prior Authorization Protocol
Proton Pump Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medi-Cal P&T Approval Date: November 15, 2017 Effective Date: January 1, 2018 This policy has been developed through review
More informationCarlo Patrono, MD, FESC. New York, 8 th December Catholic University School of Medicine, Rome, Italy. New York Cardiovascular Symposium
Aspirin in Primary and Secondary Cardiovascular Disease Prevention. Still Four Questions: About Enteric-Coated, Indicated Doses, Use in Diabetes, Use in PVD Carlo Patrono, MD, FESC Catholic University
More informationAccepted Manuscript. Correlation or Causation: Sex Hormones and Microscopic Colitis. Baldeep Pabla, Reid M. Ness
Accepted Manuscript Correlation or Causation: Sex Hormones and Microscopic Colitis Baldeep Pabla, Reid M. Ness PII: S0016-5085(18)35216-8 DOI: https://doi.org/10.1053/j.gastro.2018.11.007 Reference: YGAST
More informationOsteoporosis Update. Greg Summers Consultant Rheumatologist
Osteoporosis Update Greg Summers Consultant Rheumatologist DEFINITION OSTEOPOROSIS is LOW BONE MASS (& micro-architectural deterioration) causing AN INCREASED RISK OF FRACTURE 23 years 82 years 23 y/o
More information0BCore Safety Profile. Pharmaceutical form(s)/strength: Gastro-resistant capsules (10, 20, 40 mg) NL/H/PSUR/0058/001 Date of FAR:
0BCore Safety Profile Active substance: Omeprazole Pharmaceutical form(s)/strength: Gastro-resistant capsules (10, 20, 40 mg) P-RMS: NL/H/PSUR/0058/001 Date of FAR: 10.04.2013 CSP Drug Substance Omeprazole
More informationThe University of Mississippi School of Pharmacy
LONG TERM PERSISTENCE WITH ACEI/ARB THERAPY AFTER ACUTE MYOCARDIAL INFARCTION: AN ANALYSIS OF THE 2006-2007 MEDICARE 5% NATIONAL SAMPLE DATA Lokhandwala T. MS, Yang Y. PhD, Thumula V. MS, Bentley J.P.
More informationAntithrombotics in the elderly. Robert Gabor Kiss FESC FACC Budapest
Antithrombotics in the elderly Robert Gabor Kiss FESC FACC Budapest The patient in the elderly You are sitting in Your office prescribing drugs and observing outcome The black box from prescription to
More informationGlucose and CV disease
Glucose and CV disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic,
More informationProton Pump Inhibitors. Description. Section: Prescription Drugs Effective Date: July 1, 2014
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.09.01 Subject: Proton Pump Inhibitors Page: 1 of 7 Last Review Date: June 12, 2014 Proton Pump Inhibitors
More informationThis house believes that HRT should be the first-line prevention for postmenopausal osteoporosis: the case against
This house believes that HRT should be the first-line prevention for postmenopausal osteoporosis: the case against Juliet Compston Professor of Bone Medicine University of Cambridge School of Clinical
More informationThe Challenge. Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Anticoagulation/Stroke
Anticoagulation/Stroke Warfarin v new oral anticoagulants post PCI Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Gerry Devlin Chairs: Phillip Matsis & Tony Scott Gerry Devlin Honorary Associate
More informationProton Pump Inhibitors. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.01 Subject: Proton Pump Inhibitors Page: 1 of 6 Last Review Date: June 24, 2015 Proton Pump Inhibitors
More informationCalcium Nephrolithiasis and Bone Health. Noah S. Schenkman, MD
Calcium Nephrolithiasis and Bone Health Noah S. Schenkman, MD Associate Professor of Urology and Residency Program Director, University of Virginia Health System; Charlottesville, Virginia Objectives:
More informationComplicated issues in GI bleeding for internists? Nonthalee Pausawasdi, M.D. Faculty of Medicine Siriraj Hospital
Complicated issues in GI bleeding for internists? Nonthalee Pausawasdi, M.D. Faculty of Medicine Siriraj Hospital Complicated issues in GI bleeding; Survey results from internists Optimal resuscitation
More informationNONSTEROIDAL ANTI- INFLAMMATORY DRUGS
NONSTEROIDAL ANTI- INFLAMMATORY DRUGS MRS. M.M. HAS A 3 YR. HX OF PROGRESSIVE RIGHT HIP PAIN. THE PAIN INCREASES WITH WEIGHT BEARING ACTIVITY. PT. HAS BEEN ON ACETAMINOPHEN WITHOUT RELIEF. PERTINENT LABS
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL 1 Supplemental Table 1. ICD codes Diagnoses, surgical procedures, and pharmacotherapy used for defining the study population, comorbidity, and outcomes Study population Atrial fibrillation
More informationGASTROINTESTINAL AND ANTIEMETIC DRUGS. Submitted by: Shaema M. Ali
GASTROINTESTINAL AND ANTIEMETIC DRUGS Submitted by: Shaema M. Ali GASTROINTESTINAL AND ANTIEMETIC DRUGS by: Shaema M. Ali There are four common medical conditions involving the GI system 1) peptic ulcers
More informationDrug Class Monograph
Drug Class Monograph Class: Proton Pump Inhibitors Drugs: Aciphex Sprinkle (rabeprazole), Dexilant (dexlansoprazole), Lansoprazole, Nexium (esomeprazole capsule, esomeprazole granules), Omeprazole, Pantoprazole,
More informationIroko Pharmaceuticals Receives FDA Approval for VIVLODEX - First Low Dose SoluMatrix Meloxicam for Osteoarthritis Pain
Iroko Pharmaceuticals Receives FDA Approval for VIVLODEX - First Low Dose SoluMatrix Meloxicam for Osteoarthritis Pain VIVLODEX Developed to Align with FDA NSAID Recommendations Proven Efficacy at Low
More informationWarfarin Management-Review
Warfarin Management-Review December 18, 2012 Elaine M. Hylek, MD, MPH Director, Thrombosis Clinic and Anticoagulation Service Boston University Medical Center Areas for Discussion Implications of time
More informationTIVORBEX Now Available in U.S. Pharmacies for the Treatment of Acute Pain
TIVORBEX Now Available in U.S. Pharmacies for the Treatment of Acute Pain Second Low-Dose SoluMatrix NSAID from Iroko Now Available by Prescription PHILADELPHIA, June 29, 2015 Iroko Pharmaceuticals, LLC,
More informationPersonalized Aspirin Therapy
Personalized Aspirin Therapy Nadir Arber, MD, MSc, MHA Head - Integrated Cancer Prevention Center Tel Aviv Medical Centre and Tel Aviv University Heidelberg 2014 CRC is Preventable Early detection Chemoprevention
More informationSpectrum of Diverticular Disease. Outline
Spectrum of Disease ACG Postgraduate Course January 24, 2015 Lisa Strate, MD, MPH Associate Professor of Medicine University of Washington, Seattle, WA Outline Traditional theories and updated perspectives
More informationMEDICATION GUIDE. for the long-term treatment of conditions where your stomach makes too much acid.
MEDICATION GUIDE Pantoprazole Sodium Delayed-Release Tablets pan toe pra zole soe dee um Read this Medication Guide before you start taking pantoprazole sodium delayed-release tablets and each time you
More informationGERD DIAGNOSIS & TREATMENT DISCLOSURES 4/18/2018
GERD DIAGNOSIS & TREATMENT Subhash Chandra MBBS Assistant Professor CHI Health Clinic Gastroenterology Creighton University, School of Medicine April 28, 2018 DISCLOSURES None 1 OBJECTIVES Review update
More informationPrescribing of anti-osteoporotic therapies following the use of Proton Pump Inhibitors in general practice
Prescribing of anti-osteoporotic therapies following the use of Proton Pump Inhibitors in general practice B. McGowan, K. Bennett, J. Feely Department of Pharmacology & Therapeutics, Trinity Centre for
More information50 years of pharmacovigilance: unfinished job
50 years of pharmacovigilance: unfinished job Joan-Ramon Laporte The role of pharmacoepidemiology in medicines regulation 108 market withdrawals in F, D & UK, 1961-93 Fulminant hepatitis Liver toxicity
More informationGastrointestinal Safety of Coxibs and Outcomes Studies: What s the Verdict?
Vol. 23 No. 4S April 2002 Journal of Pain and Symptom Management S5 Proceedings from the Symposium The Evolution of Anti-Inflammatory Treatments in Arthritis: Current and Future Perspectives Gastrointestinal
More informationRisk assessment in UGIB: recent PCI & ACS. Dr Martin James PhD FRCP October 20 th 2016 Nottingham Endoscopy Masterclass
Risk assessment in UGIB: recent PCI & ACS Dr Martin James PhD FRCP October 20 th 2016 Nottingham Endoscopy Masterclass Clinical scenario 65 yr male Previous smoker, hyperlipidaemia, DM PCI < 48 hours Dual
More information